Member Info for TRENCH123

The extract I refer to is after 51 minutes of the presentation

Continued ....

It is quite possible that the company could be acquired. JM in his April 2023 presentation referred to PYC having been approached by big pharma in this regard but it 'has not come to fruition up to this point in time'

I am happy to continue to hold my PYC shares (just under 1 million) and see how the story unfolds over the next few years

It is easy to be critical and I agree that on paper the historical results are not great. However, I believe the company is committed to being a successful profit-making company

I have been a PYC shareholder for close on ten years now and have see a lot of change for the better in terms of the company's capabilities and the quality of its clients

A further potential positive I took from the presentation was in relation to the two large projects which PYC were expecting to be contracted in the the last financial year but which did not materialise. JM did suggest that these 'may yet come back, they are not cancelled just delayed at this point'

I do not believe that Innovate UK would have set in place a two year £500k + funded project involving PYC if they had any doubts about the ability of the project to be seen through to a successful conclusion and with the likelihood of some worthwhile end results. I suspect that the £300k fund raise was in some way linked to the grant application. Looking ahead, getting the precision dosing tool functioning in a live setting would likely be a game changer for PYC

I think PYC could do well to invest in a packet of Strepsils (other brands are available) for Pete Sargent !!

Good solid presentation with no surprises. Reference Merck, I was pleased to hear that PYC have 'several ongoing projects with them at this point of time'

Dosemerx are clearly pushing for PYC to develop their Precision Dosing Tool to incorporate Neutropenia and G-CSF capabilities. This could improve the chances of a decent commercial agreement with Dosemerx in the longer term

So why isn't Valirx flying ??

Two very recent releases on Youtube reference Beyond Blood's award winning technology, including reference to recent joint grant with PYC. Very exciting technology to be involved in. Watch 15 minutes onwards on first clip for Manfredi San Germano presentation

https://www.youtube.com/watch?v=Iz5z_LkKjQo&t=0s

https://www.youtube.com/watch?v=B6p1043lsl4

With reference to the proposed EUDA-Theoremrx merger, the original LOI was signed on 4th October and announced on 5th October. The LOI provided for a 30 day exclusivity period with the option of a 15 day extension at the agreement of both parties. I believe that if it were 'working days' then surely it would have specified this

My interpretation is that the 30 day exclusivity period expired on 3rd November and we are now well into the extension period with the final date for a news release being 18th November. As the 18th November falls on a Saturday, I would expect news by close of business in the US Friday night

I recognize that the new project could be seen by some as creating a further strain on cash resources. One could also argue that having a 70% Innovate grant contribution being made towards the development of a potentially valuable asset - the precision dosing tool - is a good thing. The addition of G-CSF to the tool's capability could made it a much more attractive proposition for the likes of Dosemerx. I am happy with today's announcement

Investor Meet Company 17th November. Jim Millen and Pete Sargent presenting

Be a little surprised if this doesn't end the day blue. Excellent RNS

Buy was 87000 so Laura's comments still valid

Your not Jasper by any chance ?

The swings in the share prices on AIM sometimes have to be taken with a large pinch of salt. Today we have had one-eighth of a per cent of the company issued share capital traded and we are supposedly 6.9% down

Whilst I only have a small Valirx holding now, I would love the deal to happen big style to give my decent PYC holding a well-needed boost

With regards to the fundraise, the PYC discount is not that unusual - it is the nature of the market at the moment

Light Science Technologies, were trading a 4p/share in April this year but could only raise funds at 1p/share. The low-price funding undermined shareholder confidence for the subsequent four months but is now looking much stronger and back trading close to 3p/share

What PYC is short of at the moment is news-flow. Once this happens I feel we could be in for a decent re-rate

In contrast to Valirx shareholders, EUDA shareholders appear unenthusiastic about a deal happening

Share price down from $1.55 immediately prior to the merger news on 4th October to $0.60 on pre-opening today

I would guess we must be one of only a very few companies in the UK with the relevant in-depth experience and technical ability in this area

Recent Cromos Pharma article relating to Project Optimus :-

https://www.linkedin.com/pulse/enhancing-oncology-drug-dosage-optimization-project-optimus

Jim Millen has described Project Optimus as PYC's 'sweet spot'

I was surprised by the current market cap of EUDA Health at only £14m ($17.25) as shown by Investing.com. This compares with £10m for Valirx. A big deal clearly for EUDA if the proposed merger with Theoremrx proceeds